Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Edurne San José-Enériz"'
Autor:
Edurne San José-Enériz, Naroa Gimenez-Camino, Obdulia Rabal, Leire Garate, Estibaliz Miranda, Nahia Gómez-Echarte, Fernando García, Stella Charalampopoulou, Elena Sáez, Amaia Vilas-Zornoza, Patxi San Martín-Uriz, Luis V. Valcárcel, Naroa Barrena, Diego Alignani, Luis Esteban Tamariz-Amador, Ana Pérez-Ruiz, Sebastian Hilscher, Mike Schutkowski, Ana Alfonso-Pierola, Nicolás Martinez-Calle, María José Larrayoz, Bruno Paiva, María José Calasanz, Javier Muñoz, Marta Isasa, José Ignacio Martin-Subero, Antonio Pineda-Lucena, Julen Oyarzabal, Xabier Agirre, Felipe Prósper
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-23 (2024)
Abstract Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the
Externí odkaz:
https://doaj.org/article/c19f4277205c445384d53303bce19ff2
Autor:
Sandra P. Nunes, Lucia Morales, Carolina Rubio, Ester Munera-Maravilla, Iris Lodewijk, Cristian Suárez-Cabrera, Victor G. Martínez, Mercedes Pérez-Escavy, Miriam Pérez-Crespo, Miguel Alonso Sánchez, Esther Montesinos, Edurne San José-Enériz, Xabier Agirre, Felipe Prósper, Antonio Pineda-Lucena, Rui Henrique, Marta Dueñas, Margareta P. Correia, Carmen Jerónimo, Jesús M. Paramio
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Alterations in the epigenetic machinery in both tumor and immune cells contribute to bladder cancer (BC) development, constituting a promising target as an alternative therapeutic option. Here, we have explored the effects of a novel histone
Externí odkaz:
https://doaj.org/article/2e7cebeed11f4705be37c46da8ae9498
Autor:
Marian Gimeno, Edurne San José-Enériz, Sara Villar, Xabier Agirre, Felipe Prosper, Angel Rubio, Fernando Carazo
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Artificial intelligence (AI) can unveil novel personalized treatments based on drug screening and whole-exome sequencing experiments (WES). However, the concept of “black box” in AI limits the potential of this approach to be translated into the
Externí odkaz:
https://doaj.org/article/91f44e62426944cb9d8b24cbc157b7d0
Autor:
Luis V Valcárcel, Edurne San José-Enériz, Xabier Cendoya, Ángel Rubio, Xabier Agirre, Felipe Prósper, Francisco J Planes
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 5, p e1010180 (2022)
With the frenetic growth of high-dimensional datasets in different biomedical domains, there is an urgent need to develop predictive methods able to deal with this complexity. Feature selection is a relevant strategy in machine learning to address th
Externí odkaz:
https://doaj.org/article/fa1e683e8c0745dc9fa3c36ab0a72911
Autor:
Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Yannick De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Quentin Lecocq, Edurne San José-Enériz, Stefaan Verhulst, Ken Maes, Karin Vanderkerken, Xabier Agirre, Felipe Prosper, Juan José Lasarte, Anna Mondino, Karine Breckpot
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promis
Externí odkaz:
https://doaj.org/article/f6044c9296d648419688c29e75e4e1a4
Autor:
Iñigo Apaolaza, Edurne San José-Enériz, Luis V Valcarcel, Xabier Agirre, Felipe Prosper, Francisco J Planes
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 3, p e1009395 (2022)
Synthetic Lethality (SL) is currently defined as a type of genetic interaction in which the loss of function of either of two genes individually has limited effect in cell viability but inactivation of both genes simultaneously leads to cell death. G
Externí odkaz:
https://doaj.org/article/077e783ad3e448e29da2dd4895c48394
Autor:
Antonio Garcia-Gomez, Tianlu Li, Carlos de la Calle-Fabregat, Javier Rodríguez-Ubreva, Laura Ciudad, Francesc Català-Moll, Gerard Godoy-Tena, Montserrat Martín-Sánchez, Laura San-Segundo, Sandra Muntión, Xabier Morales, Carlos Ortiz-de-Solórzano, Julen Oyarzabal, Edurne San José-Enériz, Manel Esteller, Xabier Agirre, Felipe Prosper, Mercedes Garayoa, Esteban Ballestar
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Mesenchymal stromal cells (MSCs) have been shown to support multiple myeloma (MM) development. Here, MSCs isolated from the bone marrow of MM patients are shown to have altered DNA methylation patterns and a methyltransferase inhibitor reverts MM-ass
Externí odkaz:
https://doaj.org/article/97c0cd9d38aa419d8042bda6761115e0
Autor:
Marian Gimeno, Edurne San José-Enériz, Angel Rubio, Leire Garate, Estíbaliz Miranda, Carlos Castilla, Xabier Agirre, Felipe Prosper, Fernando Carazo
Publikováno v:
Cancers, Vol 14, Iss 13, p 3251 (2022)
Recent functional genomic screens—such as CRISPR-Cas9 or RNAi screening—have fostered a new wave of targeted treatments based on the concept of synthetic lethality. These approaches identified LEthal Dependencies (LEDs) by estimating the effect o
Externí odkaz:
https://doaj.org/article/c7339b2c2ddd41d289f31345189bee12
Autor:
Edurne San José-Enériz, Xabier Agirre, Obdulia Rabal, Amaia Vilas-Zornoza, Juan A. Sanchez-Arias, Estibaliz Miranda, Ana Ugarte, Sergio Roa, Bruno Paiva, Ander Estella-Hermoso de Mendoza, Rosa María Alvarez, Noelia Casares, Victor Segura, José I. Martín-Subero, François-Xavier Ogi, Pierre Soule, Clara M. Santiveri, Ramón Campos-Olivas, Giancarlo Castellano, Maite Garcia Fernandez de Barrena, Juan Roberto Rodriguez-Madoz, Maria José García-Barchino, Juan Jose Lasarte, Matias A Avila, Jose Angel Martinez-Climent, Julen Oyarzabal, Felipe Prosper
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Epigenetic drugs are emerging as a powerful therapeutic option for cancer treatment. Here, the authors synthesized selective chemical probes that simultaneously inhibit the G9a and DNMTs methyltransferase activity and demonstrate their anti-tumour ac
Externí odkaz:
https://doaj.org/article/286f3156e84448249eb1c05f274be064
Publikováno v:
Molecular & Cellular Oncology, Vol 4, Iss 4 (2017)
Epigenetic drug discovery is an emerging strategy for the treatment of cancer and other pathologies. Here, we discuss our recent discovery of first-in-class dual reversible inhibitors of the histone methyltransferase activity of G9a/EHMT2 and DNA met
Externí odkaz:
https://doaj.org/article/6448d806d3ac4e1986b11b5499a30ee8